Steroid myopathy: Some unresolved issues

Journal of Endocrinological Investigation

Volumn 34, Issue 5, 2011, Pages 370-375

  Minetto, M A ^a,b   Lanfranco, F ^a   Motta, G ^a   Allasia, S ^a   Arvat, E ^a   D'Antona, G ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b POLITECNICO DI TORINO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Electromyography; Glucocorticoids; Motor unit; Muscle fibers

Indexed keywords

ANABOLIC AGENT; CREATINE; GLUCOCORTICOID; POTASSIUM; RECOMBINANT SOMATOMEDIN C;

CLINICAL FEATURE; CORTICOSTEROID INDUCED MYOPATHY; CUSHING SYNDROME; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MUSCLE CELL; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; SHORT SURVEY; VITAMIN SUPPLEMENTATION;

EID: 79960220442     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03347462     Document Type: Short Survey

References (79)

1. Minetto MA, Rainoldi A, Jabre JF. The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies. J Endocrinol Invest 2007, 30: 791-6. (Pubitemid 350238208)
2. Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983, 18: 155-66. (Pubitemid 13167144)
3. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001, 56 (Suppl 1): 24-8. (Pubitemid 34062892)
4. Owczarek J, Jasi ska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 2005, 57: 23-34.
5. Ruff RL, Weissmann J. Endocrine myopathies. Neurol Clin 1988, 6: 575-92.
6. sted. Philadelphia: Hanley & Belfus. 1995, 1031-129.
7. Mills GH, Kyroussis D, Jenkins P, et al. Respiratory muscle strength in Cushing's syndrome. Am J Respir Crit Care Med 1999, 160: 1762-5.
8. Hanson P, Dive A, Brucher JM, Bisteau M, Dangoisse M, Deltombe T. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20: 1371-80.
9. Pecori Giraldi F, Moro M, Cavagnini F; Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology. Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab 2003, 88: 1554-8.
10. Faludi G, Gotlieb J, Meyers J. Factors influencing the development of steroid-induced myopathies. Ann N Y Acad Sci 1966, 138: 62-72.
11. Rich MM, Pinter MJ. Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol 2003, 547: 555-66. (Pubitemid 36304987)
12. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197: 1-10.
13. Goodlad GA, Clark CM. Glucocorticoid-mediated muscle atrophy: alterations in transcriptional activity of skeletal muscle nuclei. Biochim Biophys Acta 1991, 1097: 166-70.
14. Inder WJ, Jang C, Obeyesekere VR, Alford FP. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clin Endocrinol (Oxf) 2010, 73: 126-32.
15. Jacquemin V, Butler-Browne GS, Furling D, Mouly V. IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes. J Cell Sci 2007, 120: 670-81. (Pubitemid 46437901)
16. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003, 285: E363-71.
17. Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007, 148: 452-60. (Pubitemid 46021477)
18. Yamamoto D, Ikeshita N, Matsubara T, et al. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1and MuRFL Life Sci 2008, 82: 460-6.
19. Waddell DS, Baehr LM, van den Brandt J, et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 2008, 295: E785-97.
20. Zheng B, Ohkawa S, Li H, Roberts-Wilson TK, Price SR. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J 2010, 24: 2660-9.
21. Tisdale MJ. Is there a common mechanism linking muscle wasting in various disease types? Curr Opin Support Palliat Care 2007, 1: 287-92.
22. Psarra AM, Solakidi S, Sekeris CE. The mitochondrion as a primary site of action of steroid and thyroid hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells. Mol Cell Endocrinol 2006, 246: 21-33. (Pubitemid 43238393)
23. Du J, Wang Y, Hunter R, et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A 2009, 106: 3543-8.
24. Dirks-Naylor AJ, Griffiths CL. Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009,117:1-7.
25. Du J, McEwen B, Manji HK. Glucocorticoid receptors modulate mitochondrial function: A novel mechanism for neuroprotection. Commun Integr Biol 2009, 2: 350-2.
26. Betters JL, Long JH, Howe KS, et al. Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells. Muscle Nerve 2008, 37: 203-9. (Pubitemid 351214167)
27. Horinouchi H, Kumamoto T, Kimura N, Ueyama H, Tsuda T. Myosin loss in denervated rat soleus muscle after dexamethasone treatment. Pathobiology 2005, 72: 108-16. (Pubitemid 40674993)
28. Mozaffar T, Haddad F, Zeng M, Zhang LY, Adams GR, Baldwin KM. Molecular and cellular defects of skeletal muscle in an animal model of acute quadriplegic myopathy. Muscle Nerve 2007, 35: 55-65. (Pubitemid 46052649)
29. Qian T, Guo X, Levi AD, Vanni S, Shebert RT, Sipski ML. High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 2005, 43: 199-203. (Pubitemid 40546717)
30. Ellis JT. Degeneration and regeneration in the muscles of cortisone-treated rabbits. Am J Phys Med 1955, 34: 240-3.
31. Williams RS. Triamcinolone myopathy. Lancet 1959, 1: 698-701.
32. Hagstrom JW, Roseman DM, Ellis JT. Debilitating muscular weakness and steroid therapy. A case with detailed clinical and pathological studies. Arch Neurol 1961, 5: 60-7.
33. Faludi G, Mills LC, Chayes ZW. Effect of steroids on muscle. Acta Endocrinol (Copenh) 1964, 45: 68-78.
34. D'Agostino AN, Chiga M. Cortisone myopathy in rabbits. A light and electron microscopic study. Neurology 1966, 16: 257-63.
35. Tice LW, Engel AG. The effects of glucocorticoids on red and white muscles in the rat. Am J Pathol 1967, 50: 311-33.
36. Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968, 123: 158-73.
37. Stern LZ, Gruener R, Kirkpatrick JB, Nemeth P. The fine structure of cortisone-induced myopathy. Exp Neurol 1972, 36: 530-8.
38. Braunstein PW Jr, DeGirolami U. Experimental corticosteroid myopathy. Acta Neuropathol 1981, 55: 167-72.
39. Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, De Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol 1995, 78: 629-37.
40. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153: 1958-64. (Pubitemid 26187926)
41. Foumier M, Huang ZS, Li H, Da X, Cercek B, Lewis MI. Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol 2003, 285: R34-43.
42. Engel AG. Electron microscopic observations in thyrotoxic and corticosteroid-induced myopathies. Mayo Clin Proc 1966, 41: 785-96.
43. Walsh G, DeVivo D, Olson W. Histochemical and ultrastructural changes in rat muscle. Occurrence following adrenal corticotrophic hormone, glucocorticoids, and starvation. Arch Neurol 1971, 24: 83-93.
44. Braund KG, Dillon AR, Mikeal RL, August JR. Subclinical myopathy associated with hyperadrenocorticism in the dog. Vet Pathol 1980, 17: 134-48. (Pubitemid 10106734)
45. Braund KG, Dillon AR, Mikeal RL. Experimental investigation of glucocorticoid-induced myopathy in the dog. Exp Neurol 1980, 68:50-71. (Pubitemid 10124389)
46. Horber FF, Hoppeler H, Herren D, et al. Altered skeletal muscle ultrastructure in renal transplant patients on prednisone. Kidney Int 1986, 30: 411-6. (Pubitemid 16029512)
47. Gardiner PF, Edgerton VR. Contractile responses of rat fast-twitch and slow-twitch muscles to glucocorticoid treatment. Muscle Nerve 1979, 2: 274-81. (Pubitemid 9238058)
48. Pellegrino MA, D'Antona G, Bortolotto S, et al. Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice. Exp Physiol 2004, 89: 89-100. (Pubitemid 38128857)
49. Polla B, D'Antona G, Bottinelli R, Reggiani C. Respiratory muscle fibres: specialisation and plasticity. Thorax 2004, 59: 808-17. (Pubitemid 39215381)
50. Tuncbay TO, Ketel WB, Boshes B. Cortisone effects on myoneural junction. Neurology 1965, 15: 314-20.
51. Shapiro MS, Namba T, Grob D. The effect of corticotropin on the neuromuscular junction. Morphologic studies in rabbits. Neurology 1968, 18: 1018-22.
52. Mitsui T, Umaki Y, Nagasawa M, et al. Motor neuron involvement in a patient with long-term corticosteroid administration. Intern Med 2003, 42: 862-6. (Pubitemid 37258704)
53. Chokroverty S, Reyes MG, Chokroverty M, Kaplan R. Effect of prednisolone on motor end-plate fine structure: a morphometric study in hamsters. Ann Neurol 1978, 3: 358-65.
54. Lewis MI, Monn SA, Sieck GC. Effect of corticosteroids on diaphragm fatigue, SDH activity, and muscle fiber size. J Appl Physiol 1992, 72: 293-301.
55. Lieu FK, Powers SK, Herb RA, et al. Exercise and glucocorticoid-induced diaphragmatic myopathy. J Appl Physiol 1993, 75: 763-71. (Pubitemid 23260219)
56. Polla B, Bottinelli R, Sandoli D, Sardi C, Reggiani C. Cortisone-induced changes in myosin heavy chain distribution in respiratory and hindlimb muscles. Acta Physiol Scand 1994, 151: 353-61. (Pubitemid 24229983)
57. Dekhuijzen PN, Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur Respir J 1992, 5: 997-1003.
58. Blanco C, Marazuela M, Flores J, Alvarez J. Severe respiratory failure secondary to Cushing's myopathy J Endocrinol Invest 2001, 24: 618-21.
59. Short KR, Nygren J, Bigelow ML, Nair KS. Effect of short-term prednisone use on blood flow, muscle protein metabolism, and function. J Clin Endocrinol Metab 2004, 89: 6198-207. (Pubitemid 39628434)
60. Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976, 61: 485-92.
61. Minetto MA, Botter A, Lanfranco F, Baldi M, Ghigo E, Arvat E. Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects. J Clin Endocrinol Metab 2010, 95: 1663-71.
62. van der Hoeven JH. Decline of muscle fiber conduction velocity during short-term high-dose methylprednisolone therapy. Muscle Nerve 1996, 19: 100-2.
63. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011, 78: 41-4.
64. Menezes LG, Sobreira C, Neder L, Rodrigues-Júnior AL, Martinez JA. Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats. J Appl Physiol 2007, 102: 698-703. (Pubitemid 46220901)
65. Kanda F, Takatani K, Okuda S, Matsushita T, Chihara K. Preventive effects of insulinlike growth factor-I on steroid-induced muscle atrophy. Muscle Nerve 1999, 22: 213-7. (Pubitemid 29070395)
66. Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology 2010, 151: 3706-19.
67. Robinzon B, Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology (Oxford) 1999, 38: 488-95.
68. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003, 88: 3167-76. (Pubitemid 36877490)
69. Maccario M, Tassone F, Gauna C, et al. Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH. Eur J Endocrinol 2001, 144: 251-6. (Pubitemid 32266294)
70. Wajchenberg BL, Liberman B, Giannella Neto D, et al. Growth hormone axis in cushing's syndrome. Horm Res 1996, 45: 99-107. (Pubitemid 26034771)
71. Yamamoto D, Maki T, Herningtyas EH, et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve 2010, 41: 819-27.
72. Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. J Appl Physiol 1990, 69: 1058-62. (Pubitemid 20338710)
73. Falduto MT, Young AP, Hickson RC. Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. Am J Physiol 1992, 263: E1157-63.
74. Uchikawa K, Takahashi H, Hase K, Masakado Y, Liu M. Strenuous exercise-induced alterations of muscle fiber cross-sectional area and fiber-type distribution in steroid myopathy rats. Am J Phys Med Rehabil 2008, 87: 126-33.
75. Barel M, Perez OA, Giozzet VA, Rafacho A, Bosqueiro JR, do Amaral SL. Exercise training prevents hyperinsulinemia, muscular glycogen loss and muscle atrophy induced by dexamethasone treatment. Eur J Appl Physiol 2010, 108: 999-1007.
76. LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehabil 1997, 17: 76-84. (Pubitemid 27183563)
77. Horber FF, Scheidegger JR, Grünig BE, Frey FJ. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985, 61: 83-8. (Pubitemid 15046199)
78. Horber FF, Scheidegger JR, Grünig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 1985, 15: 302-7. (Pubitemid 16185734)
79. Horber FF, Hoopeler H, Scheidegger JR, Grünig BE, Howald H, Frey FJ. Impact of physical training on the ultrastructure of midthigh muscle in normal subjects and in patients treated with glucocorticoids. J Clin Invest 1987, 79: 1181-90. (Pubitemid 17065500)